Page last updated: 2024-11-04

salicylsalicylic acid and Innate Inflammatory Response

salicylsalicylic acid has been researched along with Innate Inflammatory Response in 17 studies

salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.

Research Excerpts

Excerpt	Relevance	Reference
" Compared with curcumin and parent NSAID (salicylic acid and salsalate), topical application of A11 and B13 onto mouse ear edema, prior to TPA treatment markedly suppressed the expression of IL-1β, IL-6 and TNF-α, respectively."	3.81	Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity. ( Chen, Q; Du, Z; Huang, MT; Li, Y; Liu, W; Lu, Y; Wang, H; Yue, Y; Zhang, K; Zheng, X, 2015)
"Inflammation is strongly linked to the pathogenesis of T2DM."	3.01	Salsalate: a pleotropic anti-inflammatory drug in the treatment of diabetes, obesity, and metabolic diseases. ( Hasan, I; Rainsford, KD; Ross, JS, 2023)
"Chronic subacute inflammation is implicated in the pathogenesis of insulin resistance and type 2 diabetes."	2.73	Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. ( Aldhahi, W; Cai, D; Goldfine, AB; Lee, J; Shoelson, SE; Silver, R; Tatro, E, 2008)
"Salsalate regulated inflammation by affecting the expression of genes from MAPK signalling and NOD-like receptor signalling pathways and lipid metabolism by affecting hepatic expression of genes that favour lipid oxidation from PPAR-α signalling pathways."	1.46	Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls. ( Haluzík, M; Kazdová, L; Kuda, O; Landa, V; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Šilhavý, J; Šimáková, M; Škop, V; Strnad, H; Trnovská, J; Zídek, V, 2017)

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (11.76)	29.6817
2010's	13 (76.47)	24.3611
2020's	2 (11.76)	2.80

Authors

Authors	Studies
Liu, W	1
Li, Y	1
Yue, Y	1
Zhang, K	1
Chen, Q	1
Wang, H	1
Lu, Y	1
Huang, MT	1
Zheng, X	1
Du, Z	1
Hasan, I	1
Rainsford, KD	1
Ross, JS	1
Bigford, GE	1
Szeto, A	1
Kimball, J	1
Herderick, EE	1
Mendez, AJ	1
Nash, MS	1
Trnovská, J	1
Šilhavý, J	1
Kuda, O	1
Landa, V	1
Zídek, V	1
Mlejnek, P	1
Šimáková, M	1
Strnad, H	1
Škop, V	1
Oliyarnyk, O	1
Kazdová, L	1
Haluzík, M	1
Pravenec, M	1
Luo, Y	1
Liu, F	1
Natarajan, R	1
Shukair, N	1
Copeland, P	1
Fan, X	1
Jung, TW	1
Park, HS	1
Jeong, JH	1
Lee, T	1
Goldfine, AB	6
Buck, JS	1
Desouza, C	1
Fonseca, V	1
Chen, YD	1
Shoelson, SE	6
Jablonski, KA	1
Creager, MA	1
Rubin, MR	1
McMahon, DJ	1
Donovan, DS	1
Cremers, S	1
Dworakowski, E	1
Schaefer, EJ	2
Silverberg, SJ	1
Alderete, TL	1
Sattler, FR	1
Richey, JM	1
Allayee, H	1
Mittelman, SD	1
Sheng, X	1
Tucci, J	1
Gyllenhammer, LE	1
Grant, EG	1
Goran, MI	1
Hauser, TH	1
Salastekar, N	1
Desai, T	1
Goldfine, HL	1
Fowler, KM	1
Weber, GM	1
Welty, F	1
Clouse, M	1
Ridker, PM	1
Lagraoui, M	1
Sukumar, G	1
Latoche, JR	1
Maynard, SK	1
Dalgard, CL	1
Schaefer, BC	1
Silver, R	1
Aldhahi, W	1
Cai, D	1
Tatro, E	1
Lee, J	1
Pedersen, BK	1
Febbraio, MA	1
Jablonski, KL	1
Chonchol, M	1
Pierce, GL	1
Walker, AE	1
Seals, DR	1
Conlin, PR	1
Halperin, F	1
Koska, J	1
Permana, P	1
Schwenke, D	1
Reaven, PD	1
Fleischman, A	1
Bernier, R	1

Clinical Trials (11)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00799643]	Phase 2/Phase 3	638 participants (Actual)	Interventional	2008-11-30	Completed
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206]	Phase 4	34 participants (Actual)	Interventional	2017-11-08	Completed
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)[NCT00624923]	Phase 2/Phase 3	340 participants (Actual)	Interventional	2008-09-30	Completed
The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity[NCT00258115]	Phase 2	20 participants (Actual)	Interventional	2003-12-31	Completed
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)[NCT01775865]	Phase 2	59 participants (Actual)	Interventional	2012-09-30	Completed
Effect of Salicylate on Glucose Metabolism in Insulin Resistance States[NCT00258128]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2000-01-31	Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00392678]	Phase 2/Phase 3	277 participants (Actual)	Interventional	2006-10-31	Completed
Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach[NCT01398943]		60 participants (Actual)	Interventional	2010-09-30	Completed
Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System[NCT03341117]	Phase 3	21 participants (Actual)	Interventional	2014-12-02	Completed
Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults[NCT02130804]	Phase 1	30 participants (Actual)	Interventional	2011-07-31	Completed
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk[NCT00330733]	Phase 2/Phase 3	71 participants (Actual)	Interventional	2007-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Fasting Glucose Over Time.

(NCT00799643)
Timeframe: 48 weeks from baseline

Intervention	mg/dl (Mean)
Placebo	2.0
Salsalate	-13.1

The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.

HbA1c (%, percentage of HbA1c) change from baseline. (NCT00799643)
Timeframe: 48 weeks from baseline

Intervention	HbA1c units are % (Mean)
Placebo	-0.04
Salsalate	-0.33

Change in Cholesterol

secondary (NCT00624923)
Timeframe: Baseline to 30 mo

Intervention	mg/dL (Mean)
1- Active Pharmacologic	5.1
2- Placebo	2.0

Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT

Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo

Intervention	U/L (Mean)
1- Active Pharmacologic	-1.1
2- Placebo	-0.6

Change in Inflammation Marker: CRP

Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo

Intervention	mg/L (Mean)
1- Active Pharmacologic	-0.1
2- Placebo	-0.1

Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months

(NCT00624923)
Timeframe: Baseline to 30 months

Intervention	mm^3 (Mean)
1- Active Pharmacologic	0
2-Placebo	0

Brachial Artery Flow-mediated Dilation (FMD)

Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks

Intervention	Percent dilation (Mean)
	Baseline	4 Weeks
Placebo	3.57	2.50
Salsalate	3.49	4.60
Young Control Group	5.88	NA

Carotid-femoral Pulse Wave Velocity (CFPWV)

Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks

Intervention	cm/sec (Mean)
	Baseline	4 weeks
Placebo	785.1	740.01
Salsalate	831.3	839.6
Young Control Group	538.0	NA

Adiponectin

(NCT00258128)
Timeframe: 4 weeks

Intervention	mg/ml (Mean)
Salsalate	22.7
Placebo	10.6

Glucose

fasting glucose (NCT00258128)
Timeframe: 4 weeks

Intervention	mmol/L (Mean)
Placebo	7.1
Salsalate	6.4

Change From Baseline and Trends in Fasting Glucose Over Time

(NCT00392678)
Timeframe: 14 week

Intervention	mg/dl (Mean)
Placebo	13
Salsalate 3.0 g/d	-19
Salsalate 3.5 g/d	-14
Salsalate 4.0 g/d	-15

Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below. (NCT00392678)
Timeframe: Baseline, week 14

Intervention	pmol/l (Median)
Placebo	-3.0
Salsalate 3.0 g/d	15
Salsalate 3.5 g/d	7.6
Salsalate 4.0 g/d	27

Change in HbA1c

Change from baseline to either 14 or 26 weeks, or last HbA1c measurement prior to rescue therapy (NCT00392678)
Timeframe: 14 week

Intervention	% HbA1c (Mean)
Placebo	0
Salsalate 3.0 g/d	-0.4
Salsalate 3.5 g/d	-0.3
Salsalate 4.0 g/d	-0.5

Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1

The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward. (NCT00392678)
Timeframe: 14 week

Intervention	% (units of HbA1c) (Mean)
3.0 g/d	-0.36
3.5 g/d	-0.34
4.0 g/d	-0.49
Placebo	-0.01

Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below (NCT00392678)
Timeframe: Baseline, week 14

Intervention	C-peptide in nmol/l (Mean)
Placebo	0.10
Salsalate 3.0 g/d	-0.07
Salsalate 3.5 g/d	-0.03
Salsalate 4.0 g/d	0.03

Safety and Tolerability

See adverse event module for details. Safety and tolerability of salsalate compared to placebo as assessed by adverse events. (NCT00392678)
Timeframe: 14 weeks

Intervention	participants (Number)
Salsalate 3.0 g/d	17
Salsalate 3.5 g/d	16
Salsalate 4.0 g/d	16
Placebo	14

Change in Lipids

"Change in lipids (low-density lipoprotein cholesterol [LDL-C], non-high-density lipoprotein cholesterol [non-HDL-C], triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL C], TC/HDL-C ratio, and LDL-C/HDL-C ratio)~LDL-C/HDL-C ratio not calculated" (NCT00392678)
Timeframe: 14 week

,,,

Intervention	mg/dl (Mean)
	Cholesterol	HDL	LDL	TG	Total to HDL ratio
Placebo	0	0	0	15	0
Salsalate 3.0 g/d	8	3	15	-34	0.1
Salsalate 3.5 g/d	-1	1	3	-22	-0.1
Salsalate 4.0 g/d	6	2	8	-16	0.2

Flow-Mediated Dilation (FMD)

Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post FMD was taken approximately 110 min after baseline

Intervention	percentage of change in FMD (Mean)
	Placebo	AOC Treatment
All Controls	6.7	6.9
All COPD Patients	3.1	4.7

Pulse Wave Velocity

A measure of vascular stiffness at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post PWV was taken approximately 90 min after baseline

Intervention	m/sec (Mean)
	Placebo	AOC Treatment
All Controls	11	10
All COPD Patients	14	11

Change in Systemic Glucose Disposal- Glucose Infusion Rates

Participants were admitted to the Clinical Research Units at 06:00-08:00 hours after an overnight fast. Euglycaemic-hyperinsulinaemic clamps were conducted at baseline and at the end of the study. Because salsalate therapy appears to decrease insulin clearance leading to higher circulating insulin levels during the clamp, we reduced the infusion rate of insulin in the active treatment arm by 20% (from 100 to 80 mUm-2 min-1) at the study end. Insulin solutions were prepared by the site pharmacist so that study staff remained blinded to drug assignment. Whole-body insulin sensitivity was estimated from glucose infusion rate (GIR) during last 30 min of insulin infusions. (NCT00330733)
Timeframe: 3 months

Intervention	percent change from baseline (Median)
Placebo	1
Salsalate Therapy	6

Glucose Area Under the Curve in These Subjects

(NCT00330733)
Timeframe: 3 months

Intervention	mmol/l/hr (Mean)
Placebo	8.98
Salsalate Therapy	8.74

Endothelial Function

Endothelial-mediated arterial responses using peripheral arterial tonometry (PAT; Itamar Medical, Caesarea, Israel). (NCT00330733)
Timeframe: Baseline and 12 weeks

Intervention	index (Mean)
	Pat Index baseline	Pat Index 12 week
Placebo	1.8	1.7
Salsalate Therapy	1.9	1.7

Plasma Adiponectin

Plasma soluble Adiponectin was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Intervention	μg/ml (Median)
	Change in adiponectin at 8 weeks	Change in adiponectin at 12 weeks
Placebo	-0.5	-0.1
Salsalate Therapy	1.3	1.2

Plasma CRP

Plasma C-reactive protein was measured by PVAHS clinical laboratory. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Intervention	mg/l (Median)
	Change in CRP at 8 weeks	Change in CRP at 12 weeks
Placebo	0	-0.1
Salsalate Therapy	-0.8	-.3

Plasma Interleukin 6

Plasma IL-6 was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Intervention	pg/ml (Median)
	Change in IL-6 at 8 weeks	Change in IL-6 at 12 weeks
Placebo	0.1	0.2
Salsalate Therapy	0	0

Plasma sVCAM

Plasma soluble VCAM was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Intervention	ng/ml (Median)
	Change in sVCAM at 8 weeks	Change in sVCAM at 12 weeks
Placebo	-12	9
Salsalate Therapy	-5	171

Reviews

1 review available for salicylsalicylic acid and Innate Inflammatory Response

Article	Year
Salsalate: a pleotropic anti-inflammatory drug in the treatment of diabetes, obesity, and metabolic diseases. Inflammopharmacology, 2023, Volume: 31, Issue:6 Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Inflammation; Inte	2023

Trials

7 trials available for salicylsalicylic acid and Innate Inflammatory Response

Article	Year
Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care, 2013, Volume: 36, Issue:12 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Brachial Artery	2013
Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. Endocrine, 2015, Volume: 50, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Remodeling; Diabetes Mellitus, Type 2; Hum	2015
Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics. Obesity (Silver Spring, Md.), 2015, Volume: 23, Issue:3 Topics: Adipose Tissue; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; California; Do	2015
Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. JAMA cardiology, 2016, 07-01, Volume: 1, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Humans; Hydroxymethylglu	2016
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and translational science, 2008, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Calorimetry; Diabetes Mellitus, Type 2; Dose	2008
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia, 2013, Volume: 56, Issue:4 Topics: Adiponectin; Adipose Tissue; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide	2013
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008
Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Dietary Carbohydrates; Double-Blind M	2008

Other Studies

9 other studies available for salicylsalicylic acid and Innate Inflammatory Response

Article	Year
Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity. Bioorganic & medicinal chemistry letters, 2015, Aug-01, Volume: 25, Issue:15 Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Ear; Edema; Inf	2015
Cardiometabolic risks and atherosclerotic disease in ApoE knockout mice: Effect of spinal cord injury and Salsalate anti-inflammatory pharmacotherapy. PloS one, 2021, Volume: 16, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Atherosclerosis; Body Weight; Cardiometabolic Ri	2021
Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls. PloS one, 2017, Volume: 12, Issue:6 Topics: Adipose Tissue, Brown; Animals; Animals, Genetically Modified; C-Reactive Protein; Fatty Acids, None	2017
Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study. International clinical psychopharmacology, 2018, Volume: 33, Issue:2 Topics: Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; C-Reactive P	2018
Salsalate ameliorates the atherosclerotic response through HO-1- and SIRT1-mediated suppression of ER stress and inflammation. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2019, Volume: 68, Issue:8 Topics: Atherosclerosis; Chemokine CCL2; Endoplasmic Reticulum Stress; Heme Oxygenase-1; Human Umbilical Vei	2019
Informative Neutral Studies Matter-Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention. JAMA cardiology, 2016, 07-01, Volume: 1, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Attention; Blood Glucose; Cardiovascular Diseases; Humans;	2016
Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain, behavior, and immunity, 2017, Volume: 61 Topics: Animals; Brain; Brain Injuries, Traumatic; Cell Line; Gene Flow; Inflammation; Macrophages; Male; Mi	2017
Diabetes: Treatment of diabetes mellitus: new tricks by an old player. Nature reviews. Endocrinology, 2010, Volume: 6, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Type 2; Endocrinology; History, 19th Cen	2010
25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:1 Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Aged; Brachial Artery; Endothelium, Vascular; Female; Huma	2011